Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension

NCT00219180 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2005
Completion date
September 30, 2006
Enrollment
1,797 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension